Table 11.
Subgroup analysis of the included randomized controlled trials
| TG | TC | LDL | |||||||
| Number | Combined Effect Value | Heterogeneity | Number | Combined Effect Value | Heterogeneity | Number | Combined Effect Value | Heterogeneity | |
| SMD (95%CI) mmol/L | I2 | SMD (95%CI) mmol/L | I2 | SMD (95%CI) mmol/L | I2 | ||||
| overall | 15 | -0.66(-1.17, -0.16)* | 89.50% | 14 | -0.43(-0.86, -0.01)* | 81.90% | 13 | -0.44(-0.88, -0.01)* | 83.00% |
| Totals | |||||||||
| ≥ 50 | 5 | -0.83(-1.08, -0.58)* | 85.90% | 5 | -0.65(-1.02, -0.01)* | 58.90% | 5 | -0.56(-1.02, -0.11)* | 73.40% |
| < 50 | 10 | -0.41(-0.62, -0.2)* | 93.70% | 9 | -0.35(-1.07, 0.38) | 85.70% | 8 | -0.46(-1.19, 0.27) | 86.30% |
| Age | |||||||||
| ≥ 50 | 8 | -0.29(-0.5, -0.08)* | 64.80% | 7 | -0.18(-0.55, 0.2) | 58.70% | 7 | -0.15(-0.65, 0.35) | 76.20% |
| < 50 | 7 | -1.02(-1.28, -0.77)* | 93.60% | 7 | -0.93(-1.76, -0.09)* | 88.80% | 6 | -0.93(-1.71, -0.15)* | 87.90% |
| Dosage | |||||||||
| ≥ 1000 | 4 | -1.41(-1.7,-1.13)* | 94.40% | 3 | -0.53(-1.32, 0.19) | 78.10% | 2 | -0.36(-1.16, 0.45) | 80.90% |
| < 1000 | 8 | -0.17(-0.4, 0.06) | 74.10% | 8 | -0.47(-1.17, 0.22) | 86.60% | 8 | -0.63(-1.36, 0.1) | 88.00% |
| Duration | |||||||||
| ≥ 10w | 13 | -0.51(-0.69, -0.34)* | 89.50% | 13 | -0.37(-0.82, 0.07) | 81.90% | 12 | -0.40(-0.86, 0.07) | |
| < 10w | 2 | -1.09(-1.54, -0.64)* | 92.50% | 2 | -1.09(-1.66, -0.52)* | 1 | -0.99(-1.55, -0.43)* | 83.30% | |
| Dietary intervention | |||||||||
| none | -1.82(-3.66, 0.03) | 91.90% | 3 | -10.22(-29.81, 9.37) | 97.30% | 2 | -4.70(-13.54, 4.14) | 96.90% | |
| regular | -0.40(-0.70, -0.11) | 44.30% | 5 | -0.55(-0.90, -0.21) | 44.70% | 5 | -0.54(-0.97, -0.12) | 64.40% | |
| advised | -0.46(-1.61, 0.69) | 94.30% | 6 | -0.16(-0.67, 0.35) | 74.40% | 6 | -0.07(-0.62, 0.48) | 77.70% | |
| Oral form | |||||||||
| row | 1 | -0.54(-1.07, 0.00) | 1 | '-1.09(-1.66, -0.53) | 1 | '-0.99(-1.55, -0.43) | |||
| aged | 2 | -0.68(-1.20, -0.17) | 54.30% | 1 | '-0.23(-0.76, 0.30) | 1 | '-0.05(-0.58, 0.48) | ||
| produced | 12 | -0.69(-1.36, -0.01) | 91.60% | 13 | '-0.40(-0.90, 0.10) | 83.40% | 11 | '-0.45(-0.97, 0.07) | 84.60% |
| HDL | SBP | DBP | |||||||
| Number | Combined Effect Value | Heterogeneity | Number | Combined Effect Value | Heterogeneity | Number | Combined Effect Value | Heterogeneity | |
| SMD (95%CI) mmol/L | I2 | SMD (95%CI) mmol/L | I2 | SMD (95%CI) mmol/L | I2 | ||||
| overall | 15 | 0.1(-0.28, 0.48) | 82.80% | 9 | -0.56(-1.58, 0.47) | 95.1 | 9 | -1.33(-2.14, -0.53)* | 92.10% |
| Totals | |||||||||
| ≥ 50 | 5 | 0.45(0.08, 0.82)* | 61.50% | 2 | -6.52(-19.26, 6.23) | 95.10% | 2 | -9.42(-26.77, 7.94) | 98.50% |
| < 50 | 10 | -0.09(-0.66, 0.47) | 86.10% | 7 | 0.27(-0.71, 1.25) | 93.50% | 7 | -0.83(-1.39, -0.26)* | 81.70% |
| Age | |||||||||
| ≥ 50 | 8 | 0.33(-0.16, 0.81) | 80.10% | 6 | -1.51(-2.65, -0.37)* | 94.10% | 6 | -1.52(-2.62, -0.43)* | 93.30% |
| < 50 | 7 | -0.16(-0.79, 0.46) | 86.00% | 3 | 1.64(-0.92, 4.20) | 97.00% | 3 | -1.19(-2.61, 0.23) | 92.30% |
| Dosage | |||||||||
| ≥ 1000 | 4 | 0.42(-0.47, 1.31) | 91.40% | 2 | 2.25(-4.65, 9.16) | 98.80% | 2 | -1.23(-2.21, -0.26)* | 92.30% |
| < 1000 | 8 | -0.15(-0.64, 0.34) | 76.60% | 7 | -1.08(-2.03, -0.12)* | 92.30% | 7 | -1.83(-3.59, -0.07)* | 92.10% |
| Duration | |||||||||
| ≥ 10w | 13 | 0.14(-0.28, 0.55) | 83.10% | 7 | -0.42(-0.85, 0.01) | 73.10% | 7 | -0.59(-0.90, -0.29)* | 46.30% |
| < 10w | 2 | -0.10(-1.32, 1.12) | 88.30% | 2 | -3.60(-22.14, 14.94) | 99.20% | 2 | -10.45(-25.76,4.86) | 98.10% |
| Dietary intervention | |||||||||
| none | 3 | -0.92(-1.69, -0.16) | 65.00% | 2 | 2.53(-3.85, 8.90) | 98.50% | -1.80(-3.65, 0.04) | 91.70% | |
| regular | 6 | 0.42(-0.02, 0.86) | 74.60% | 3 | -3.82(-6.62, -1.03) | 97.40% | -4.33(-7.18, -1.48) | 97.30% | |
| advised | 6 | 0.26(-0.36, 0.88) | 82.50% | 4 | -0.23(-0.62, 0.16) | 34.90% | -0.54(-0.90, -0.19) | 20.80% | |
| Oral form | |||||||||
| row | 1 | 0.51(-0.03, 1.05) | - | - | - | - | - | - | - |
| aged | 2 | 0.88(-0.03, 1.79) | 84.60% | 2 | -7.07(-18.71, 4.56) | 98.30% | 2 | -9.56(-26.63, 7.52) | 98.50% |
| produced | 12 | -0.07(-0.49, 0.35) | 80.30% | 7 | 0.41(-0.48, 1.29) | 91.90% | 7 | '-0.78(-1.35, -0.22) | 81% |
*p < 0.05, statistically significant, CI Confidence interval, TG Triglycerides, TC Total cholesterol, LDL-c Low-density lipoprotein cholesterol, HDL-c High-density lipoprotein cholesterol, SBP Systolic blood pressure, DBP Diastolic blood pressure